Dynamic Landscape for Cell and Gene Therapy in 2024
2024 is an exciting time to be involved in the cell and gene therapy (CGT) industry. With rapid advancements in science, the industry is on the cusp of industrializing and standardizing the manufacturing and commercialization of CGT products. The future points toward standardized setups and more automated systems. However, the broad nature of the field necessitates a variety of approaches.
To help understand and navigate this market, Kalorama Information’s latest report, Cell Therapy and Gene Therapy Markets (Markets by Disease Type) 2023-2029, presents comprehensive market segments, estimates, forecasts, development pipelines, and the competitive landscape for key cell and gene therapeutic areas.
Transformative Impact on Medical Treatment
Cell and gene therapy products are revolutionizing the treatment of cancer and genetic diseases. These therapies are also expanding aggressively into other medical areas, including neurological, autoimmune, cardiovascular, musculoskeletal, and dermatological diseases, among others.
Kalorama Information estimates that sales in the cell and gene therapy market exceeded $10 billion in 2023 and are projected to experience double-digit growth through 2029. Key segments that will experience the strongest growth rates over the next several years include cardio/non-oncology blood, oncology, and musculoskeletal.
Rapid Progress and Challenges
Therapies for blood cancers and neurological conditions have shown rapid progress, while other segments are still primarily in clinical trials. Solid tumors present a significant opportunity but remain challenging. Kalorama Information anticipates that the next few years will witness rapid evolution in various CGT areas as a range of new products get approved. Despite increasing global connectivity, regional trends show variations in approvals.
Global Trends in Cell and Gene Therapy
The CGT field spans almost all therapeutic areas, but some global trends are notable:
- Technological advancements
- Extension of indications
- Regional expansion and approvals
- Manufacturing and scaling challenges and improvements
- New business models addressing affordability and accessibility
Factors Contributing to Success
The success of certain therapies often depends on similar factors, including:
- Additional approvals for indications or regions
- Increased awareness and resources for diseases
- Availability of new diagnostics
- Enhanced patient access through partners and networks
- Addressed supply chain and scaling challenges
- Negotiated reimbursement programs and alternative payment models
About the Report
Stay informed about the rapidly evolving cell and gene therapy market with the Cell Therapy and Gene Therapy Markets (Markets by Disease Type) 2023-2029 report from Kalorama Information. Dive deep into market dynamics, technological advancements, and competitive landscapes to navigate the future of CGT.
The report provides detailed chapters covering market estimates and forecasts, the development pipeline, and the competitive landscape for the following segments:
- Oncology
- Neurology
- Musculoskeletal
- Dermatology
- Cardiology/Non-Oncology Blood
- Other
Market estimates represent global and regional sales for 2023 and projected markets for 2029. Competitors’ product revenues and estimates are provided for 2023, with forecasts up to 2029.
